recent publications

• academic article

  • Firstenberg, M. S., Dyke, C. M., Angiolillo, D. J., Ramaiahm, C., Price, M., Brtko, M., Welsby, I., Chandna, H., Holmes, D. R., Voeltz, M., Tummala, P., Hutyra, M., et al. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery Heart Surgery Forum  2013 16:E60-E69  DOI:10.1532/hsf98.20121103  PMID:23625478
  • Bhatt, D. L., Pare, G., Eikelboom, J. W., Simonsen, K. L., Emison, E. S., Fox, K. A. A., Steg, P. G., Montalescot, G., Bhakta, N., Hacke, W., Flather, M. D., Mak, K. H., et al. The relationship between cyp2c19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: The charisma genetics study European Heart Journal  2012 33:2143-2150  DOI:10.1093/eurheartj/ehs059  PMID:22450429
  • Angiolillo, D. J., Firstenberg, M. S., Price, M. J., Tummala, P. E., Hutyra, M., Welsby, I. J., Voeltz, M. D., Chandna, H., Ramaiah, C., Brtko, M., Cannon, L., Dyke, C., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery a randomized controlled trial JAMA-Journal of the American Medical Association  2012 307:265-274  DOI:10.1001/jama.2011.2002  PMID:22253393  PMCID:PMC3774162
  • Berger, J. S., Bhatt, D. L., Steg, P. G., Steinhubl, S. R., Montalescot, G., Shao, M. Y., Hacke, W., Fox, K. A., Berger, P. B., Topol, E. J., Lincoff, A. M., Investigators, Charisma Bleeding, mortality, and antiplatelet therapy: Results from the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (charisma) trial American Heart Journal  2011 162:98-105  DOI:10.1016/j.ahj.2011.04.015  PMID:21742095
  • Weber, M., Bhatt, D. L., Brennan, D. M., Hankey, G. J., Steinhubl, S. R., Johnston, S. C., Montalescot, G., Mak, K. H., Fox, K. A. A., Easton, D. J., Topol, E. J., Hamm, C. W., et al. High-sensitivity c-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: A substudy from the charisma trial Heart  2011 97:626-631  DOI:10.1136/hrt.2010.210419  PMID:21393433
  • Topol, E. J., Bousser, M. G., Fox, K. A. A., Creager, M. A., Despres, J. P., Easton, J. D., Hamm, C. W., Montalescot, G., Steg, P. G., Pearson, T. A., Cohen, E., Gaudin, C., et al. Rimonabant for prevention of cardiovascular events (crescendo): A randomised, multicentre, placebo-controlled trial Lancet  2010 376:517-523  DOI:10.1016/s0140-6736(10)60935-x  PMID:20709233
  • Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M. Y., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., Topol, E. J., Investigators, Charisma Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease Circulation  2010 121:2575-2583  DOI:10.1161/circulationaha.109.895342  PMID:20516378
  • Montalescot, G., Ellis, S. G., de Belder, M. A., Janssens, L., Katz, O., Pluta, W., Ecollan, P., Tendera, M., van Boven, A. J., Widimsky, P., Andersen, H. R., Betriu, A., et al. Enoxaparin in primary and facilitated percutaneous coronary intervention a formal prospective nonrandomized substudy of the finesse trial (facilitated intervention with enhanced reperfusion speed to stop events) JACC-Cardiovascular Interventions  2010 3:203-212  DOI:10.1016/j.jcin.2009.11.012  PMID:20170878
  • Berger, J. S., Bhatt, D. L., Steinhubl, S. R., Shao, M. Y., Steg, P. G., Montalescot, G., Hacke, W., Fox, K. A., Lincoff, A. M., Topol, E. J., Berger, P. B., Investigators, Charisma Smoking, clopidogrel, and mortality in patients with established cardiovascular disease Circulation  2009 120:2337-2344  DOI:10.1161/circulationaha.109.866533  PMID:19933933  PMCID:PMC2814172
  • Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., Peruga, J. Z., Hamankiewicz, M., Pluta, W., et al. 1-year survival in a randomized trial of facilitated reperfusion results from the finesse (facilitated intervention with enhanced reperfusion speed to stop events) trial JACC-Cardiovascular Interventions  2009 2:909-916  DOI:10.1016/j.jcin.2009.07.009  PMID:19850248
  • Herrmann, H. C., Lu, J. D., Brodie, B. R., Armstrong, P. W., Montalescot, G., Betriu, A., Neuman, F. J., Effron, M. B., Barnathan, E. S., Topol, E. J., Ellis, S. G., Investigators, Finesse Benefit of facilitated percutaneous coronary intervention in high-risk st-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals JACC-Cardiovascular Interventions  2009 2:917-924  DOI:10.1016/j.jcin.2009.06.018  PMID:19850249
  • Collet, J. P., Montalescot, G., Steg, P. G., Steinhubl, S. R., Fox, K. A. A., Hu, T. F., Johnston, S. C., Hamm, C. W., Bhatt, D. L., Topol, E. J. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the charisma trial Archives of Cardiovascular Diseases  2009 102:485-496  DOI:10.1016/j.acvd.2009.03.012  PMID:19664568
  • Dasgupta, A., Steinhubl, S. R., Bhatt, D. L., Berger, P. B., Shao, M. Y., Mak, K. H., Fox, K. A. A., Montalescot, G., Weber, M. A., Haffner, S. M., Dimas, A. P., Steg, P. G., et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial) American Journal of Cardiology  2009 103:1359-1363  DOI:10.1016/j.amjcard.2009.01.342  PMID:19427428
  • Mak, K. H., Bhatt, D. L., Shao, M., Haffner, S. M., Hamm, C. W., Hankey, G. J., Johnston, S. C., Montalescot, G., Steg, P. G., Steinhubl, S. R., Fox, K. A. A., Topol, E. J. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease European Heart Journal  2009 30:857-865  DOI:10.1093/eurheartj/ehp037  PMID:19233855
  • Steinhubl, S. R., Bhatt, D. L., Brennan, D. M., Montalescot, G., Hankey, G. J., Eikelboom, J. W., Berger, P. B., Topol, E. J., Investigators, Charisma Aspirin to prevent cardiovascular disease: The association of aspirin dose and clopidogrel with thrombosis and bleeding Annals of Internal Medicine  2009 150:379-386  DOI:10.7326/0003-4819-150-6-200903170-00006  PMID:19293071
  • Eikelboom, J. W., Hankey, G. J., Thom, J., Bhatt, D. L., Steg, P. G., Montalescot, G., Johnston, S. C., Steinhubl, S. R., Mak, K. H., Easton, J. D., Hamm, C., Hu, T. F., et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid determinants and effect on cardiovascular risk Circulation  2008 118:1705-1712  DOI:10.1161/circulationaha.108.768283  PMID:18838564
  • Ellis, S. G., Tendera, M., de Belder, M. A., van Boven, A. J., Widimsky, P., Janssens, L., Andersen, H. R., Betriu, A., Savonitto, S., Adamus, J., Peruga, J. Z., Kosmider, M., et al. Facilitated pci in patients with st-elevation myocardial infarction New England Journal of Medicine  2008 358:2205-2217  DOI:10.1056/NEJMoa0706816  PMID:18499565
  • Wang, T. H., Bhatt, D. L., Fox, K. A. A., Steinhubl, S. R., Brennan, D. M., Hacke, W., Mak, K. H., Pearson, T. A., Boden, W. E., Steg, P. G., Flather, M. D., Montalescot, G., et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the charisma trial European Heart Journal  2007 28:2200-2207  DOI:10.1093/eurheartj/ehm274  PMID:17673448
  • Bhatt, D. L., Flather, M. D., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Hamm, C. W., Hankey, G. J., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the charisma trial Journal of the American College of Cardiology  2007 49:1982-1988  DOI:10.1016/j.jacc.2007.03.025  PMID:17498584
  • Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events New England Journal of Medicine  2006 354:1706-1717  DOI:10.1056/NEJMoa060989  PMID:16531616
  • Bhatt, D. L., Fox, K. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., Flather, M. D., Haffner, S. M., et al. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial American Heart Journal  2005 150:401.e1-401.e7  DOI:10.1016/j.ahj.2005.03.017  PMID:16169314
  • Ellis, S. G., Armstrong, P., Betriu, A., Brodie, B., Herrmann, H., Montalescot, G., Neumann, F. J., Smith, J. J., Topol, E., Investigators, Finesse Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: Design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (finesse) trial American Heart Journal  2004 147  DOI:10.1016/j.ahj.2003.07.025
  • Anderson, K. M., Califf, R. M., Stone, G. W., Neumann, F. J., Montalescot, G., Miller, D. P., Ferguson, J. J., Willerson, J. T., Weisman, H. F., Topol, E. J. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention Journal of the American College of Cardiology  2001 37:2059-2065  DOI:10.1016/s0735-1097(01)01290-6  PMID:11419888